Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
High Risk Cervical CancerAdvanced Cervical Cancer
Interventions
DRUG

ADXS11-001

DRUG

Placebo

Trial Locations (117)

704

Site, Tainan City

1812

Site, Seoul

3080

Site, Seoul

3203

Site, Elche

3331

Site, Taoyuan District

3722

Site, Seoul

5505

Site, Seoul

6273

Site, Seoul

6351

Site, Seoul

7120

Site, Palma de Mallorca

7198

Site, Palma de Mallorca

8035

Site, Barcelona

8041

Site, Barcelona

8208

Site, Sabadell

8908

Site, Barcelona

10002

Site, Taipei

10630

Site, Taipei

11000

Site, Belgrade

11080

Site, Belgrade

11259

Site, Taipei

12208

Albany

13200

Site, Pulau Pinang

13496

Site, Seongnam

14004

Site, Córdoba

15586

Site, Kota Bharu

16150

Site, Kota Bharu

17007

Site, Girona

21029

Site, Vinnytsia

21204

Site, Kamenitz

28046

Site, Madrid

28050

Site, Madrid

29009

Site, Khmelnytskyi

29010

Site, Málaga

31217

Site, Chihuahua City

34000

Site, Kragujevac

36011

Site, Poltava

40705

Site, Taichung

41013

Site, Seville

43018

Site, Lutsk

45219

Site, Cincinnati

46000

Site, Ternopil

46009

Site, Valencia

46010

Site, El Palmar

Site, Valencia

49102

Site, Dnipro

50009

Site, Zaragoza

50612

Site, Yangsan

58013

Site, Chernivtsi

59100

Site, Kuala Lumpur

61070

Site, Kharkiv

68000

Site, Ampang

76018

Site, Ivano-Frankivsk

92868

Site, Orange

115478

Site, Moscow

163045

Site, Arkhangelsk

197758

Site, Saint Petersburg

198255

Site, Saint Petersburg

249036

Site, Obninsk

350040

Site, Krasnodar

354057

Site, Sochi

357502

Site, Pyatigorsk

360000

Site, Nal'chik

400131

Site, Volgograd

450054

Site, Ufa

460021

Site, Orenburg

603006

Site, Nizhny Novgorod

4810469

SITE, Temuco

7500836

SITE, Santiago

Unknown

Mobile

Site, Phoenix

Phoenix

Duarte

Long Beach

Orange

Site, San Francisco

Site, Miami

Site, Tallahassee

Tampa

Augusta

Maywood

Site, Park Ridge

Site, Indianapolis

Indianapolis

Iowa City

Scarborough

Site, Baltimore

Detroit

Minneapolis

Site, Omaha

Site, Las Vegas

Site, Hackensack

Site, Brooklyn

Charlotte

Winston-Salem

Site, Hilliard

Kettering

Oklahoma City

Philadelphia

Greenville

Chattanooga

Nashville

Site, Dallas

Site, Galveston

Houston

Milwaukee

Site, Rostov-on-Don

Site, Zaporizhzhya

07103

Site, Newark

F5300 COE

Site, La Rioja

20220-410

Site, Rio de Janeiro

59075-740

Site, Natal

T2N4N2

SITE, Calgary

H2X0A9

SITE, Montreal

J1H5N4

Site, Sherbrooke

CP 06760

Site, Mexico City

15-027

Site, Bialystok

20-090

Site, Lublin

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Advaxis, Inc.

INDUSTRY

NCT02853604 - Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer | Biotech Hunter | Biotech Hunter